Glucose News and Research

RSS

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

Researchers discover key role of RAP1 gene in obesity

The discovery of an unexpected function for a gene that was associated to another process in the organism might be a solution in search of a problem, a clue to unsuspected connections. That is what has happened with RAP1, a gene that protects telomeres- the ends of chromosomes-after researchers from the Spanish National Cancer Research Centre surprisingly discovered its key role in obesity.

21 Jun 2013

Walnuts can play role in protecting against heart disease

Promising results from a new study published in the Journal of the American College of Nutrition provide convincing evidence that walnuts can help protect against heart disease.

20 Jun 2013

GSMA announces first-of-its-kind clinical study for its mHealth Grand Tour

The GSMA today announced a first-of-its-kind clinical study for its mHealth Grand Tour in September 2013, which is designed to raise awareness of diabetes and promote the development and delivery of mHealth solutions in partnership with the International Diabetes Federation European Region (IDF Europe).

19 Jun 2013

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia—low blood sugar—compared with the commercially available insulin glargine, a new meta-analysis study finds.

19 Jun 2013

Research: Fetal exposure to BPA causes inflammation in fat tissues after birth

New research suggests that fetal exposure to the common environmental chemical bisphenol A, or BPA, causes increased inflammation in fat tissues after birth, which can lead to obesity and metabolic syndrome. Results of the animal study were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

19 Jun 2013

Stress exposure may be associated with increased risk of aggressive breast cancer

Local chemical signals released by fat cells in the mammary gland appear to provide a crucial link between exposure to unrelenting social stressors early in life, and the subsequent development of breast cancer, researchers from the University of Chicago report in the July 2013 issue of the journal Cancer Prevention Research.

19 Jun 2013

Mendor's groundbreaking diabetes management platform receives CE mark

Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance. This cloud-based platform seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry.

18 Jun 2013

PTS to integrate CardioChek PA system into Aegis workforce wellness programs

Polymer Technology Systems, Inc. announced a partnership with Aegis Health Group to integrate the CardioChek PA system into Aegis workforce wellness programs administered by health systems across the country.

18 Jun 2013

Combination of obesity and low testosterone increases risk of diabetes and brain damage

Low testosterone worsens the harmful effects of obesity in the nervous system, a new study in mice finds. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

FGF21 endocrine hormone which reduces glucose levels also protects against cardiac diseases in mice

A research group has found that FGF21, an endocrine factor which reduces glucose levels, protects against cardiac diseases in mice. The research, published online on the journal Nature Communications, was led by Francesc Villarroya, professor from the Department of Biochemistry and Molecular Biology of the UB and Director of the Institute of Biomedicine of the University of Barcelona (IBUB), affiliated centre with the campus of international excellence BKC.

18 Jun 2013

Overweight women who skip breakfast experience acute insulin resistance

Overweight women who skip breakfast experience acute, or rapid-onset, insulin resistance, a condition that, when chronic, is a risk factor for diabetes, a new study finds. The results, which were presented Sunday at The Endocrine Society's 95th Annual Meeting in San Francisco, suggest that regularly skipping breakfast over time may lead to chronic insulin resistance and thus could increase an individual's risk for type 2 diabetes.

18 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Researchers use patient-specific stem cells to correct deficient insulin-producing cells

A team from the New York Stem Cell Foundation Research Institute and the Naomi Berrie Diabetes Center of Columbia University has generated patient-specific beta cells, or insulin-producing cells, that accurately reflect the features of maturity-onset diabetes of the young.

18 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

Mount Sinai researchers present several new studies at ENDO 2013

Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.

17 Jun 2013

Too much sugar can lead to heart failure, shows study

Too much sugar can set people down a pathway to heart failure, according to a study led by researchers at The University of Texas Health Science Center at Houston (UTHealth).

15 Jun 2013

Glucose News and Research

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

Researchers discover key role of RAP1 gene in obesity

Walnuts can play role in protecting against heart disease

GSMA announces first-of-its-kind clinical study for its mHealth Grand Tour

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Research: Fetal exposure to BPA causes inflammation in fat tissues after birth

Stress exposure may be associated with increased risk of aggressive breast cancer

Mendor's groundbreaking diabetes management platform receives CE mark

PTS to integrate CardioChek PA system into Aegis workforce wellness programs

Combination of obesity and low testosterone increases risk of diabetes and brain damage

FGF21 endocrine hormone which reduces glucose levels also protects against cardiac diseases in mice

Overweight women who skip breakfast experience acute insulin resistance

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Researchers use patient-specific stem cells to correct deficient insulin-producing cells

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

Mount Sinai researchers present several new studies at ENDO 2013

Too much sugar can lead to heart failure, shows study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News